Ekaterina Baryshnikova

Dr. Ekaterina Baryshnikova

Cardiothoracic Anesthesia and Intensive Care, IRCCS Policlinico San Donato, San Donato Milanese, Italy
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
Marco RanucciMarco Ranucci
Marco Ranucci
Ekaterina BaryshnikovaEkaterina Baryshnikova
Ekaterina Baryshnikova
SCserenella castelvecchio
serenella castelvecchio
GPGabriele Pelissero
Gabriele Pelissero

20 November 2011 in Critical Care
Verified
Journal Article
Open access
PDF file
Marco RanucciMarco Ranucci
Marco Ranucci
ABAndrea Ballotta
Andrea Ballotta
HKHassan Kandil
Hassan Kandil
GIGiuseppe Isgrò
Giuseppe Isgrò
CCConcetta Carlucci
Concetta Carlucci
TGthe Surgical and Clinical Outcome Research Group
the Surgical and Clinical Outcome Research Group
Introduction: Extracorporeal membrane oxygenation (ECMO) after cardiac operations (postcardiotomy) is commonly used for the treatment of acute heart failure refractory to drug treatment. Bleeding and thromboembolic events are the most common complications of postcardiotomy ECMO. The present study is a retrospective comparison of the conventional heparin-based anticoagulation protocol with a bivalirudin-based, heparin-free protocol. Endpoints of this study are blood loss, allogeneic blood product use, and costs during the ECMO procedure. Methods: A retrospective study was undertaken in the setting of cardiac surgery, anesthesia, and intensive care departments of a university research hospital. Twenty-one patients (12 adults and nine children) who underwent postcardiotomy ECMO from 2008 through 2011 were retrospectively analyzed. The first consecutive eight patients were treated with heparin-based anticoagulation (H-group) and the next 13 consecutive patients with bivalirudin-based anticoagulation (B-group). The following parameters were analyzed: standard coagulation profile, thromboelastographic parameters, blood loss, allogeneic blood products use, thromboembolic complications, and costs during the ECMO treatment. Results: Patients in the B-group had significantly longer activated clotting times, activated partial thromboplastin times, and reaction times at thromboelastography. The platelet count and antithrombin activity were not significantly different, but in the H-group a significantly higher amount of platelet concentrates, fresh frozen plasma, and purified antithrombin were administered. Blood loss was significantly lower in the B-group, and the daily cost of ECMO was significantly lower in pediatric patients treated with bivalirudin. Thromboembolic complications did not differ between groups. Conclusions: Bivalirudin as the sole anticoagulant can be safely used for postcardiotomy ECMO, with a better coagulation profile, less bleeding, and allogeneic transfusions. No safety issues were raised by this study, and costs are reduced in bivalirudin-treated patients.

1 January 2011 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
Marco RanucciMarco Ranucci
Marco Ranucci
Ekaterina BaryshnikovaEkaterina Baryshnikova
Ekaterina Baryshnikova
GSGiorgio Soro
Giorgio Soro
ABAndrea Ballotta
Andrea Ballotta
DBDonatella De Benedetti
Donatella De Benedetti
DCDaniela Conti
Daniela Conti

15 June 2015 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
Marco RanucciMarco Ranucci
Marco Ranucci
Ekaterina BaryshnikovaEkaterina Baryshnikova
Ekaterina Baryshnikova
GCGiulia Beatrice Crapelli
Giulia Beatrice Crapelli
NRNiels Rahe‐Meyer
Niels Rahe‐Meyer
LMLorenzo A. Menicanti
Lorenzo A. Menicanti
TGthe Surgical Clinical Outcome REsearch (SCORE) Group
the Surgical Clinical Outcome REsearch (SCORE) Group
Background: Postoperative bleeding after heart operations is still a common finding, leading to allogeneic blood products transfusion. Fibrinogen and coagulation factors deficiency are possible determinants of bleeding. The experimental hypothesis of this study is that a first‐line fibrinogen supplementation avoids the need for fresh frozen plasma ( FFP ) and reduces the need for any kind of transfusions. Methods and Results: This was a single‐center, prospective, randomized, placebo‐controlled, double‐blinded study. One‐hundred sixteen patients undergoing heart surgery with an expected cardiopulmonary bypass duration >90 minutes were admitted to the study. Patients in the treatment arm received fibrinogen concentrate after protamine administration; patients in the control arm received saline solution. In case of ongoing bleeding, patients in the treatment arm could receive prothrombin complex concentrates ( PCC s) and those in the control arm saline solution. The primary endpoint was avoidance of any allogeneic blood product. Patients in the treatment arm had a significantly lower rate of any allogeneic blood products transfusion (odds ratio, 0.40; 95% confidence interval, 0.19 to 0.84, P =0.015). The total amount of packed red cells and FFP units transfused was significantly lower in the treatment arm. Postoperative bleeding was significantly ( P =0.042) less in the treatment arm (median, 300 mL; interquartile range, 200 to 400 mL) than in the control arm (median, 355 mL; interquartile range, 250 to 600 mL). Conclusions: Fibrinogen concentrate limits postoperative bleeding after complex heart surgery, leading to a significant reduction in allogeneic blood products transfusions. No safety issues were raised. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01471730.

10 September 2014 in British Journal of Anaesthesia
Verified
Journal Article
Open access
PDF file
Marco RanucciMarco Ranucci
Marco Ranucci
DCD. Colella
D. Colella
Ekaterina BaryshnikovaEkaterina Baryshnikova
Ekaterina Baryshnikova
UDU. Di Dedda
U. Di Dedda
Drugs that act on the platelet P2Y12 receptor are responsible for postoperative bleeding in cardiac surgery. However, protease-activated receptor (PAR) that reacts to thrombin stimulation might still be active in patients treated with P2Y12 inhibitors. Preoperative platelet function testing could possibly guide the timing of surgery. We investigated the association between P2Y12 receptor and PAR inhibition and bleeding after cardiac surgery. A retrospective cohort study of 361 patients undergoing cardiac surgery and treated with P2Y12 anti-platelet agents was undertaken. All patients received a preoperative multiplate electrode aggregometry testing of platelet P2Y12 receptor activity (ADPtest) and PAR reactivity with thrombin receptor-activating peptide (TRAP) stimulation. ADPtest and TRAPtest data measured before surgery were analysed for association with postoperative bleeding (ml per 12 h) and severe postoperative bleeding. Both the ADPtest and the TRAPtest were significantly (P=0.001) associated with postoperative bleeding. A threshold of 22 U for the ADPtest yielded a negative predictive value (NPV) of 94% and a positive predictive value (PPV) of 20%, and a threshold of 75 U for the TRAPtest yielded an NPV of 95% and a PPV of 23%. In the subgroup of patients with ADPtest <22 U, TRAPtest ≥75 U was not associated with severe bleeding (NPV of 100% and PPV of 37%). In patients taking P2Y12 receptor inhibitors, residual platelet reactivity to thrombin stimulation limits the risk of severe postoperative bleeding.

28 October 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Marco RanucciMarco Ranucci
Marco Ranucci
clementina sitziaclementina sitzia
clementina sitzia
Ekaterina BaryshnikovaEkaterina Baryshnikova
Ekaterina Baryshnikova
UDUmberto Di Dedda
Umberto Di Dedda
RCRosanna Cardani
Rosanna Cardani
Massimiliano Marco Corsi RomanelliMassimiliano Marco Corsi Romanelli
Massimiliano Marco Corsi Romanelli
Background: Coronavirus Disease 2019 (COVID-19)-associated coagulopathy is characterized by a prothrombotic state not yet comprehensively studied. We investigated the coagulation pattern of patients with COVID-19 acute respiratory distress syndrome (ARDS), comparing patients who survived to those who did not. Methods: In this prospective cohort study on 20 COVID-19 ARDS patients, the following biomarkers were measured: thrombin generation (prothrombin fragment 1 + 2 (PF 1 + 2)), fibrinolysis activation (tissue plasminogen activator (tPA)) and inhibition (plasminogen activator inhibitor 2 (PAI-2)), fibrin synthesis (fibrinopeptide A) and fibrinolysis magnitude (plasmin–antiplasmin complex (PAP) and D-dimers). Measurements were done upon intensive care unit (ICU) admission and after 10–14 days. Results: There was increased thrombin generation; modest or null release of t-PA; and increased levels of PAI-2, fibrinopeptide A, PAP and D-dimers. At baseline, nonsurvivors had a significantly (p = 0.014) higher PAI-2/PAP ratio than survivors (109, interquartile range (IQR) 18.1–216, vs. 8.7, IQR 2.9–12.6). At follow-up, thrombin generation was significantly (p = 0.025) reduced in survivors (PF 1 + 2 from 396 pg/mL, IQR 185–585 to 237 pg/mL, IQR 120–393), whereas it increased in nonsurvivors. Fibrinolysis inhibition at follow-up remained stable in survivors and increased in nonsurvivors, leading to a significant (p = 0.026) difference in PAI-2 levels (161 pg/mL, IQR 50–334, vs. 1088 pg/mL, IQR 177–1565). Conclusion: Severe patterns of COVID-19 ARDS are characterized by a thrombin burst and the consequent coagulation activation. Mechanisms of fibrinolysis regulation appear unbalanced toward fibrinolysis inhibition. This pattern ameliorates in survivors, whereas it worsens in nonsurvivors.